Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Beta-adrenolytics in heart failure--are they all really equal?].

Krzysztof J Filipiak1, Grzegorz Opolski

  • 1I Katedra i Klinika Kardiologii Akademii Medycznej w Warszawie. krzysztof.filipiak@amwaw.edu.pl

Przeglad Lekarski
|April 21, 2006
PubMed
Summary

The Carvedilol or Metoprolol European Trial (COMET) indicated carvedilol improved survival in heart failure patients more than metoprolol. Beta-blockers are not all equal; carvedilol

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of urban versus rural utilization of the Polish Helicopter Emergency Medical Service in patients with ST-segment elevation myocardial infarction.

Kardiologia polska·2020
Same author

Assessing sex differences in patients with takotsubo syndrome requires homogeneous cohorts. Authors' reply.

Polish archives of internal medicine·2020
Same author

Trends in antithrombotic management of patients with atrial fibrillation. A report from the Polish part of the EURObservational Research Programme - Atrial Fibrillation General Long-Term Registry.

Polish archives of internal medicine·2020
Same author

Do older patients get takotsubo syndrome differently?

Journal of geriatric cardiology : JGC·2020
Same author

Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: Preliminary results from the randomized TORNADO trial.

Cardiology journal·2020
Same author

Optimal ECG Lead System for Exercise Assessment of Ischemic Heart Disease.

Journal of cardiovascular translational research·2019

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure management often involves beta-blockers like carvedilol and metoprolol.
  • The Carvedilol or Metoprolol European Trial (COMET) compared these two drugs.
  • Debate exists regarding the equivalence of target doses used in trials.

Purpose of the Study:

  • To analyze the comparative efficacy of carvedilol and metoprolol in heart failure patients.
  • To investigate potential differences in pharmacological profiles and ancillary properties.
  • To assess the impact on all-cause mortality and beta-adrenoceptor blocking activity.

Main Methods:

  • Comparison of outcomes between carvedilol and immediate-release metoprolol groups in the COMET trial.
  • Assessment of all-cause mortality and heart rate reduction as indicators of beta-blockade.
  • Review of ancillary properties of carvedilol not present in metoprolol.

Main Results:

  • Carvedilol demonstrated a survival benefit over metoprolol in the COMET trial.
  • All-cause mortality was lower in the carvedilol group.
  • Metoprolol's beta(1)-adrenoceptor blocking activity appeared suboptimal in the trial compared to carvedilol.

Conclusions:

  • Beta-adrenolytics used in heart failure are not therapeutically equivalent.
  • Carvedilol exhibits a mortality benefit over metoprolol at the doses used in COMET.
  • Ancillary properties of carvedilol may contribute to its distinct position in heart failure treatment.

Related Experiment Videos